Saltar al contenido
MilliporeSigma

Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.

Brain & development (2010-07-16)
Vincenzo Belcastro, Laura Pierguidi, Nicola Tambasco
RESUMEN

Several new antiepileptic drugs (AEDs) have been introduced for clinical use recently. These new AEDs, like the classic AEDs, target multiple cellular sites both pre- and postsynaptically. The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection. Recent observations suggest that levetiracetam is both safe and effective against post-stroke seizures. In this review, the potential neuroprotective role in brain ischemia and the therapeutic implications of levetiracetam in post-stroke epilepsy are discussed.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Levetiracetam, ≥98% (HPLC)
Supelco
Levetiracetam, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
Levetiracetam, United States Pharmacopeia (USP) Reference Standard
Levetiracetam, European Pharmacopoeia (EP) Reference Standard